Drug developer Redx Pharma Plc is to present a pre-clinical profile of its exciting new Porcupine inhibitor at a cancer conference in Munich later today.
Drugs like Redx’s RXC004 work by targeting cancer stems cells that can often lie dormant after traditional treatment and are associated with a recurrence of the illness. Read more . . .